4D-310 in Adults With Fabry Disease and Cardiac Involvement

Summary

This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease and cardiac involvement

Timeline

Start

2022-10-16

Primary completion

2026-06

Completion

2030-06

Drugs

Indications